GRHL2 and sarcoma: Similarly, GRHL2 – a transcription factor that can inhibit EMT (Varma et al., 2012; Walentin et al., 2015) – can be methylated in sarcomas as compared to carcinoma (Somarelli et al., 2016b), thus rewiring the circuit regulating EMT in sarcomas.